Literature DB >> 29636424

Frequency of Patent Foramen Ovale and Migraine in Patients With Cryptogenic Stroke.

Brian H West1, Nabil Noureddin2, Yakov Mamzhi1, Christopher G Low3, Alexandra C Coluzzi1, Evan J Shih1, Rubine Gevorgyan Fleming1, Jeffrey L Saver4, David S Liebeskind4, Andrew Charles4, Jonathan M Tobis5.   

Abstract

BACKGROUND AND
PURPOSE: Individuals with migraine are at higher risk for stroke, but the mechanism has not been established. On the basis of the association between migraine and intracardiac right-to-left shunt, it has been proposed that stroke in migraineurs could be caused by a paradoxical embolus passing through a patent foramen ovale (PFO) or pulmonary arteriovenous malformation. The aim of this study was to determine the prevalence of PFO with right-to-left shunt in patients who presented with cryptogenic stroke and had a history of migraine.
METHODS: Patients between 18 and 60 years old who presented with an ischemic stroke were characterized based on ASCOD phenotyping (atherosclerosis; small-vessel disease; cardiac pathology; other causes; dissection). A migraine diagnosis was identified by reviewing physician notes, and frequent aura was defined if present in at least 50% of attacks. A PFO with right-to-left shunt diagnosis was identified by the presence of a positive bubble contrast study with either transcranial Doppler, transthoracic, or transesophageal echocardiography.
RESULTS: Of the 712 patients who presented with ischemic stroke, 127 (18%) were diagnosed as cryptogenic; 68 patients had adequate testing for PFO and a documented migraine history. The prevalence of PFO in patients with cryptogenic stroke without migraine was elevated (59%) compared with the general population (18%). Patients with both cryptogenic stroke and migraine had a higher prevalence of PFO (79%). In patients with cryptogenic stroke who had migraine with frequent aura, the prevalence of PFO was 93%. Only 5 patients (4%) had a history compatible with migrainous infarction.
CONCLUSIONS: In patients with cryptogenic stroke who have migraine, there is a high prevalence (79%) of PFO with right-to-left shunt. The timing of the stroke in migraineurs is usually not related to a migraine attack. These observations are consistent with the hypothesis that the mechanism of stroke in migraineurs is most likely because of a paradoxical embolus. Future cryptogenic stroke classification schemes should consider including PFO as a separate etiologic category.
© 2018 American Heart Association, Inc.

Entities:  

Keywords:  cryptogenic stroke; migraine; patent foramen ovale

Mesh:

Year:  2018        PMID: 29636424      PMCID: PMC5915909          DOI: 10.1161/STROKEAHA.117.020160

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  44 in total

1.  Contemporary management of patent foramen ovale.

Authors:  Bernhard Meier; James E Lock
Journal:  Circulation       Date:  2003-01-07       Impact factor: 29.690

2.  Studies on headache; long-term observations of the reactivity of the cranial arteries in subjects with vascular headache of the migraine type.

Authors:  M M TUNIS; H G WOLFF
Journal:  AMA Arch Neurol Psychiatry       Date:  1953-11

3.  Migraine, shear stress, and platelet serotonin.

Authors:  J David Spence
Journal:  Headache       Date:  2013-03       Impact factor: 5.887

4.  Transcranial Doppler is Complementary to Echocardiography for Detection and Risk Stratification of Patent Foramen Ovale.

Authors:  Joshua Tobe; Chrysi Bogiatzi; Claudio Munoz; Arturo Tamayo; J David Spence
Journal:  Can J Cardiol       Date:  2015-12-18       Impact factor: 5.223

5.  Relation of atrial shunts to migraine in patients with ischemic stroke and peripheral emboli.

Authors:  Peter Wilmshurst; Simon Nightingale; Matthew Pearson; Lindsay Morrison; Kevin Walsh
Journal:  Am J Cardiol       Date:  2006-08-02       Impact factor: 2.778

Review 6.  Migrainous infarction: aspects on risk factors and therapy.

Authors:  Katarina Laurell; Erik Lundström
Journal:  Curr Pain Headache Rep       Date:  2012-06

7.  Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke.

Authors:  Jeffrey L Saver; John D Carroll; David E Thaler; Richard W Smalling; Lee A MacDonald; David S Marks; David L Tirschwell
Journal:  N Engl J Med       Date:  2017-09-14       Impact factor: 91.245

8.  Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study.

Authors:  Stewart J Tepper; Carl G H Dahlöf; Andrew Dowson; Lawrence Newman; Hank Mansbach; Martin Jones; Ba Pham; Chris Webster; Reijo Salonen
Journal:  Headache       Date:  2004-10       Impact factor: 5.887

9.  A meta-analysis of case-control studies of the association of migraine and patent foramen ovale.

Authors:  Hisato Takagi; Takuya Umemoto
Journal:  J Cardiol       Date:  2015-10-31       Impact factor: 3.159

10.  Visual migraine aura with or without headache: association with right to left shunt and assessment following transcutaneous closure.

Authors:  M Khalid Mojadidi; Hamidreza Khessali; Rubine Gevorgyan; Ralph D Levinson; Jonathan M Tobis
Journal:  Clin Ophthalmol       Date:  2012-07-17
View more
  20 in total

Review 1.  Maternal Stroke: an Update.

Authors:  Maria D Zambrano; Eliza C Miller
Journal:  Curr Atheroscler Rep       Date:  2019-06-22       Impact factor: 5.113

2.  Prevalence and clinical profile of migraine with aura in a cohort of young patients with stroke: a preliminary retrospective analysis.

Authors:  Claudia Altamura; Angelo Cascio Rizzo; Paola Maggio; Giovanna Viticchi; Matteo Paolucci; Nicoletta Brunelli; Gianluca Cecchi; Fabrizio Fiacco; Mauro Silvestrini; Fabrizio Vernieri
Journal:  Neurol Sci       Date:  2019-05       Impact factor: 3.307

3.  Relation of Patent Foramen Ovale to Acute Mountain Sickness.

Authors:  Brian H West; Rubine Gevorgyan Fleming; Bashar Al Hemyari; Pooya Banankhah; Kenneth Meyer; Leslie H Rozier; Linda S Murphy; Alexandra C Coluzzi; Joshua L Rusheen; Preetham Kumar; David Elashoff; Jonathan M Tobis
Journal:  Am J Cardiol       Date:  2019-03-18       Impact factor: 2.778

4.  14th EUNOS Congress: PORTO, PORTUGAL, 16-19 JUNE 2019.

Authors: 
Journal:  Neuroophthalmology       Date:  2019-06-07

5.  Assessing patent foramen ovale on coronary computed tomographic angiography: a comparison with transesophageal echocardiography.

Authors:  Li Xiong; Yingting Zeng; Tian Gan; Feifei Yan; Jiao Bai; Yanbin Shi; Xiaoyue Zhou; Yu Wu; Xiaochun Zhang
Journal:  Jpn J Radiol       Date:  2022-01-26       Impact factor: 2.374

Review 6.  Migraine and cerebrovascular disease: still a dangerous connection?

Authors:  Elio Clemente Agostoni; Marco Longoni
Journal:  Neurol Sci       Date:  2018-06       Impact factor: 3.307

7.  Investigation of patent foramen ovale as a mechanism for brain metastasis in patients without prior lung involvement.

Authors:  R Levin-Epstein; P Kumar; J Rusheen; R G Fleming; Z McWatters; W Kim; T B Kaprealian; B West; J M Tobis
Journal:  Clin Transl Oncol       Date:  2020-08-13       Impact factor: 3.405

8.  Shorter visual aura characterizes young and middle-aged stroke patients with migraine with aura.

Authors:  Claudia Altamura; Angelo Cascio Rizzo; Giovanna Viticchi; Paola Maggio; Carmelina Maria Costa; Nicoletta Brunelli; Giuditta Giussani; Matteo Paolucci; Fabrizio Fiacco; Vincenzo Di Lazzaro; Elio Clemente Agostoni; Mauro Silvestrini; Fabrizio Vernieri
Journal:  J Neurol       Date:  2021-06-24       Impact factor: 6.682

9.  A comparison of contrast transthoracic echocardiography and contrast transcranial Doppler in cryptogenic stroke patients with patent foramen ovale.

Authors:  Jie Chen; Luyun Chen; Wangwang Hu; Xianda Ni; Zengrui Zhang; Xiaowen Feng; Zijian Fan; Cuiping Chen; Fengzhen Qiu; Bei Shao
Journal:  Brain Behav       Date:  2019-04-02       Impact factor: 2.708

Review 10.  Migraine and risk of stroke.

Authors:  Lise R Øie; Tobias Kurth; Sasha Gulati; David W Dodick
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-03-26       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.